Andrew Nesbitt

Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents

Andrew Nesbitt, Gianluca Fossati, Marianne Bergin et al. · Inflammatory Bowel Diseases · 2007 · 465 citations

Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

Sue Stephens, Spencer Emtage, Olivia M. Vetterlein et al. · PubMed · 1995 · 124 citations

Immunology, Immunoediting, Pathology +17

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

Roger Palframan, Michael Airey, Adrian Moore et al. · Journal of Immunological Methods · 2009 · 119 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13

Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer

Charlene Porter, Sylvia Armstrong‐Fisher, Tim Kopotsha et al. · Journal of Reproductive Immunology · 2016 · 111 citations · Full text

Vitro Transcytosis, Laboratory Immunology, Immunology +25

The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.

A Morgan, Nick D. Jones, Andrew Nesbitt et al. · PubMed · 1995 · 104 citations

Histocompatibility, Hla, Hla Immunogenetics +21